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ABSTRACT
Persistent cellular proliferation and metabolic reprogramming are essential 
processes in carcinogenesis. Here, we performed Gene Set Enrichment Analysis 
(GSEA) and found that that LETM1, a mitochondrial calcium transporter, is associated 
with cellular growth signals such as platelet-derived growth factor (PDGF) receptor 
signaling and insulin signaling pathways. These results were then verified by qRT-
PCR and immnunoblotting. Mechanistically, up-regulation of LETM1 induced YAP1 
nuclear accumulation, increasing the expression of PDGFB, PDGFRB and THBS4. 
Consistent with this, LETM1 silencing caused loss of YAP1 nuclear signal, decreasing 
the expression of PDGFB, PDGFRB and THBS4. Immunohistochemical staining 
consistently indicated a positive association between LETM1 up-regulation, YAP1 
nuclear localization and high PDGFB expression. In clinical data analysis, LETM1 up-
regulation in thyroid cancer was found to be related to aggressive tumor features 
such as lymphovascular invasion (LVI, P < 0.001) and lymph node metastasis (LNM, 
P = 0.011). Multivariate analysis demonstrated that LETM1 up-regulation increases 
the risk of LVI and LNM (OR = 3.455, 95% CI = 1.537–7.766 and OR = 3.043, 95% 
CI = 1.282–7.225, respectively). Collectively, these data suggest that up-regulation 
of LETM1 induces sustained activation of proliferative signaling pathways, such as 
PDGF signal pathway by AKT induced YAP1 transactivation, resulting in aggressive 
thyroid cancer phenotypes.
INTRODUCTION
Most cases of thyroid cancer, the most common 
endocrine malignancy, have a generally favorable 
prognosis [1]. However, 10–15% of thyroid cancers 
present as persistent or recurrent disease, sometimes 
resulting in terminal disease [2, 3]. To develop molecular 
markers able to predict these persistent or recurrent cases, 
research over the last decade based on molecular and 
systems biology has remarkably improved the mechanistic 
understanding of thyroid carcinogenesis [4, 5]. As a result 
of our increased understanding of the pathogenesis of 
thyroid cancer, aberrant activation of MEK/ERK and/
or phosphatidylinositol-3 kinase (PI3K)/AKT pathways 
are known to play fundamental roles in thyroid cancer 
progression [6, 7].
In addition to sustaining proliferative signaling, 
metabolic alterations driven by oncogenic signaling 
pathways are now understood to contribute to the 
development of thyroid carcinogenesis [8]. Aerobic 
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glycolysis, also called the “Warburg effect”, drives 
metabolic remodeling in PTEN-deficient thyroid cells [9]. 
Crosstalk between oncogenic BRAFV600E kinase and the 
mitochondria also increases glycolytic activity in thyroid 
cancer cells [10]. However, our recent observation indicated 
that a subset of papillary thyroid cancer (PTC) is able to 
sustain mitochondrial capacity [11]. In agreement with this 
finding, human melanomas exhibit increased mitochondrial 
capacity and resistance to oxidative stress through the 
activation of melanocyte lineage-specification transcription 
factor (MITF) and PGC1α (PPARGC1A) [12, 13]. 
Furthermore, addiction to oxidative phosphorylation 
(OxPhos) generates drug resistance against PLX4720, a 
BRAF inhibitor, in BRAF-mutated melanomas [14]. 
Leucine zipper EF-hand containing transmembrane 
protein 1 (LETM1), which was first discovered in patients 
with Wolf-Hirschhorn syndrome (WHS), has been 
reported to enhance mitochondrial Ca2+ transport and cell 
proliferation [15–17]. Silencing of LETM1 expression 
influenced autophagy activity and provoked AMPK 
activation and cell cycle arrest [17]. Furthermore, LETM1 
promotes AKT/PKB activation by inhibition of C-terminal 
modulator protein (CTMP) [18]. Supporting the proto-
oncogenic properties of LETM1, human multiple tissues 
arrays have also demonstrated increased expression of 
LETM1 in various cancers, including breast, head and 
neck cancers [19, 20]. 
In this study, we found that up-regulation of LETM1 
expression is related to platelet-derived growth factor 
(PDGF) signaling, supporting the role of LETM1 in cell 
proliferation and energy metabolism in PTC. Remarkably, 
LETM1 over-expression is also linked to nuclear retention 
of Yes-associated protein 1 (YAP1), which upregulates 
PDGFB at the transcriptional level, while LETM1 
silencing has the opposite effect. Based on these findings, 
up-regulation of LETM1 appears to play a critical role in 
altering mitochondrial metabolism and tumor behavior in 
PTC carcinogenesis through YAP1 transactivation.
RESULTS
Up-regulation of LETM1 linked to PDGF signal 
pathway
First, to verify our hypothesis that LETM1 
expression might be linked to the cell growth signaling 
pathway, we performed correlation analysis using public 
data (EPFL/LISP BXD CD Muscle Affy Mouse Gene 1.0 
ST (Nov12) RMA Exon Level, muscle mRNA; number of 
samples = 42) deposited at GeneNetwork. Compatible with 
previous reports, Letm1 showed positive correlations with 
Ndufv1 (encoding NADH:Ubiquinone Oxidoreductase 
Core Subunit V1), Sdhb (Succinate Dehydrogenase 
Complex Iron Sulfur Subunit B) (Figure 1A), Cyc1 
(Cytochrome C1), Atp5b (ATP Synthase, H+ Transporting, 
Mitochondrial F1 Complex, Beta Polypeptide) (Figure 1B), 
Mrpl12 (Mitochondrial Ribosomal Protein L12) (INIA 
Adrenal Affy MoGene 1.0ST (Jun12) RMA Males, 
adrenal mRNA; number of samples = 46, Supplementary 
Figure S1A), Ndufb7 (NADH:Ubiquinone Oxidoreductase 
Subunit B7), Cox5b (Cytochrome C Oxidase Subunit 5B), 
Uqcrc1 (Ubiquinol-Cytochrome C Reductase Core 
Protein I), Mrpl39 (Mitochondrial Ribosomal Protein 
L39) and Tomm40 (Translocase Of Outer Mitochondrial 
Membrane 40) (EPFL/LISP BXD CD Muscle Affy Mouse 
Gene 1.0 ST (Nov12) RMA Exon Level) (Figure 1C, 
Supplementary Figure S1B–S1D). Interestingly, Letm1 
expression positively correlated with mechanistic target 
of rapamycin (Mtor) and phosphoinositide-3-kinase, 
regulatory subunit 4 (Pik3r4) (Figure 1D). In addition, 
Gene Set Enrichment Analysis (GSEA) using public 
repository data (GSE33630, expression profiling by array 
of 11 anaplastic thyroid carcinomas (ATC), 49 PTC and 
45 normal thyroids (N)) showed that platelet-derived 
growth factor (PDGF) signaling pathway was coordinately 
enriched in PTC with high LETM1 expression (P = 0.022, 
FDR q-value < 0.05, Figure 1E). To support our findings 
from GeneNetwork and GSE33630, we performed GSEA 
using public repository data from “The Cancer Genome 
Atlas”. The comparison of mean RPKM (Reads Per 
Kilobase per Million mapped reads) between normal and 
tumor mRNAs indicated statistically significant increase 
of LETM1 expression in PTC (Figure 2A). In the TCGA 
analysis, 15 cases out of 505 PTC (total THCA) showed 
high expression of LETM1. Although 15 was a small 
proportion of the total PTCs in THCA, only a small subset 
of PTCs had demonstrated aggressive behavior in the 
clinical setting, therefore we decided to select 30 cases; 15 
cases with the highest expression (Highest LETM1 PTC) 
and 15 cases with the lowest expression (Lowest LETM1 
PTC) of LETM1. Performing GSEA based on TPM 
(Transcripts per Million), gene sets related to oxidative 
phosphorylation, glycolysis and gluconeogenesis and 
insulin signaling pathway were coordinately enriched 
in high LETM1 group (Supplementary Table S1, Figure 
2B). Remarkably, volcano plot generated from selected 
30 TCGA cases used in our GSEA indicated significantly 
increased fold changes of representative genes of PDGF 
signaling pathway such as PDGFB, platelet-derived 
growth factor receptor, beta polypeptide (PDGFRB), 
Thrombospondin-4 (THBS4), collagen, type IV, alpha 1 
(COL4A1), platelet derived growth factor D (PDGFD) and 
collagen, type IV, alpha 5 (COL4A5) (Figure 2C). qRT-
PCR experiments using our own cDNA samples from 
patients with PTC supported our GSEA analysis. PDGFB, 
PDGFRB and THBS4 were increased in PTC with high 
LETM1 expression (high LETM1 PTC, Figure 2D, 
Supplementary Table S2). Many hormones or hormone-
binding proteins such as PDGFB are enhanced by YAP1 
overexpression in MCF10A cells. Although mRNA of 
YAP1 was not increased, the mRNA expression of coronin 
2B (CORO2B), a representative YAP1 target gene, was 
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significantly increased in high LETM1 PTC (Figure 2C 
and 2D) [21]. 
Effects of LETM1 on growth factor signaling 
and OxPhos
To confirm the changes in expression of mRNAs 
encoding for regulators of growth factor signaling and 
OxPhos, we performed western blot analysis using 
samples derived from human thyroid cancer tissues. As 
shown in Figure 3A, we observed that PTC showing high 
LETM1 expression (high LETM1 PTC) also had high 
expression of components of OxPhos, such as SDHB, 
UQCRC2, ATP5A and HSP60, a mitochondrial heat 
shock protein. With regard to growth factor signaling 
intermediates, AKT phosphorylation (pAKT) and PDGFB 
were markedly increased in high LETM1 PTC, whereas 
pAKT and PDGFB were decreased in PTC with low 
LETM1 expression (low LETM1 PTC), compared to 
paired normal thyroid tissue (Figure 3A and 3B). When we 
overexpressed LETM1 in a human PTC cell line (BCPAP), 
we observed a coordinate increase in protein levels of 
OxPhos components (SDHB, UQCRC2 and MTCO1; 
Figure 3C). Interestingly, LETM1 overexpressing 
BCPAP cells showed increased glycolysis and oxygen 
consumption, implying that these cells uptake glucose 
rapidly and generate large amounts of ATP by OxPhos 
(Supplementary Figure S2). Furthermore, supporting 
the relationship between LETM1 with growth factor 
signaling, LETM1 overexpression increased AKT and 
pAKT in BCPAP (Figure 3C and 3D), associated with 
elevated protein levels of PDGFB and mRNA expression 
of PDGFB, PDGFBR and THBS4 (Figure 3C and 3E).
Up-regulation or silencing of LETM1 is linked to 
YAP1 localization
YAP1 transactivation is regulated by subcellular 
localization of YAP1 [22]. When LATS phosphorylates 
YAP1 at serine 127 residue, YAP1 is exported from 
Figure 1: Correlation of LETM1 expression with genes related to OxPhos and cellular proliferation signaling. 
(A–D) Correlation of Letm1 mRNA expression with genes related to OxPhos and mTOR/PI3K signaling from public repository data in 
GeneNetwork (a free scientific web resource, http://www.genenetwork.org/; INIA Adrenal Affy MoGene 1.0ST (Jun12) RMA Males, 
EPFL/LISP BXD CD Muscle Affy Mouse Gene 1.0 ST (Nov12) RMA Exon Level). (E) Correlation of LETM1 mRNA expression with 
genes related to the PDGF signaling pathway from the Gene Expression Omnibus (GEO) of NCBI (Gene expression data available at www.
ncbi.nlm.nih.gov/projects/geo; accession no. GSE33630).
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nucleus and transactivation is turned off [21]. In 
contrast, activation of G-protein coupled receptors 
or receptor tyrosine kinase signaling promotes YAP1 
nuclear translocation and YAP1-dependent transcription 
via PI3K-AKT/PKB signaling activation [23, 24]. 
Consistent with this regulatory mechanism of YAP1 
subcellular localization, when we performed double 
immunofluorescence (IF) staining for YAP1 and LETM1, 
we consistently observed that LETM1 overexpression 
increased the nuclear accumulation of YAP1 in BCPAP 
cells (Figure 4A). Next, to investigate the involvement 
of the PI3K-PKB/AKT signaling pathway in YAP1 
regulation by LETM1, we treated BCPAP cells with 
LY294002, a PI3K inhibitor, and performed IF staining. 
Remarkably, LY294002 was able to abolish the nuclear 
signal of YAP1 (Figure 4A), which was associated with 
the disappearance of AKT phosphorylation (Figure 4B). 
To verify YAP1 regulation by LETM1, we also treated 
BCPAP cells with siLETM1 and observed a markedly 
decreased YAP1 nuclear signal (Figure 4C), accompanied 
by disappearance of AKT phosphorylation (Figure 4D). 
Taken together, nuclear accumulation of YAP1 could be 
prevented by the inactivation of PI3K-AKT signaling or 
down-regulation of LETM1.
Clinical impact of LETM1 up-regulation in 
thyroid cancer
Reinforcing our observations regarding the 
relationship of LETM1 with cellular growth signaling, 
LETM1 silencing resulted in decreased protein levels of 
PDGFB and mRNA expression of PDGFB, PDGFBR and 
THBS4 in BCPAP cells (Figure 4D and 4E) and 8505C 
cells (human anaplastic thyroid cancer cell line, Figure 4F 
and 4G). Furthermore, consistent with the IF data, PTC 
with high immunohistochemical staining (IHC-P) scores 
of LETM1 showed moderate to strong signals for nuclear 
YAP1 and PDGFB (Figure 4H, Table 1). To investigate the 
impact of LETM1 over-expression on clinical outcome, 
we performed statistical analyses of the relationship 
Figure 2: Correlation of LETM1 expression with genes related to OxPhos and cellular proliferation signaling. 
(A) Comparison of LETM1 RPKM values between normal thyroid tissues (NL) and papillary thyroid cancer (CA) using public data from 
The Cancer Genome Atlas Research Network (TCGA, http://cancergenome.nih.gov/). (B) GSEA using PTCs with the highest and lowest 
LETM1 expression levels (each group n = 15). (C) Volcano plot analysis indicating increased RPKM values (log2 fold change) of central 
components of the PDGF signaling pathway. (D) qRT-PCR using validation cDNA sets from the study subjects. White and blue bars 
indicate matched normal thyroid tissues and PTC, respectively (each group n = 7). Comparisons of the average means were performed with 
the Mann-Whitney U-test. Data are presented as the means ± SD. ** P < 0.01, *** P < 0.001. All P-values are two-sided. 
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between LETM1 IHC staining intensities and clinico-
pathological parameters. Remarkably, the lymphovascular 
invasion (LVI) and lymph node metastasis (LNM) were 
more frequently observed in patients with PTC showing 
moderate to strong LETM1 staining intensities (Table 2). 
In addition, multivariate analysis clearly indicated that 
moderate to strong LETM1 staining intensities increased 
risks of LVI and LNM even after adjusting the clinico-
pathological parameters (OR = 4.724, CI = 1.423–15.688, 
Table 3; OR = 2.333, CI = 1.059–5.141, Table 4). 
DISCUSSION
LETM1, localized in the inner membrane of 
mitochondria, is an element of Ca2+/H+ antiporter and 
functions in mitochondrial ATP production and biogenesis 
[15]. Recently, some authors have claimed that high 
expression levels of LETM1 have correlation with poor 
prognostic factors in human malignancies [19, 20]. In our 
study, compatible to previous knowledge, the correlation 
analysis using GeneNetwork indicated that Letm1 mRNA 
expression levels had strong positive correlation with 
mRNA expressions of genes related to OxPhos such as 
Ndufv1, Sdhb, Cyc1, Atp5b and so forth. Interestingly, our 
GSEA using repository data by the International Pathology 
Panel of the Chernobyl Tissue Bank (GSE33630) indicated 
that PDGF signaling was coordinately enriched in high 
LETM1 expression PTC. Furthermore, our analyses using 
TCGA database consistently indicated that PTCs have high 
expression levels of LETM1 compared to normal thyroid 
tissue and that high LETM1 expression was significantly 
associated with expression of genes related to OxPhos. 
Figure 3: Correlation of LETM1 expression with oxidative phosphorylation (OxPhos) and cellular proliferation 
signaling. (A and B) Representative western blot analyses indicating the association between LETM1 and OxPhos/PDGFB in tissue 
samples from human papillary thyroid cancers and paired normal thyroid (A), and quantification of total and phospho-AKT band intensities. 
White and green bars indicate matched normal thyroid tissues and PTC, respectively (B). (C to E) Representative western blot analyses 
indicating the effect of LETM1 overexpression on OxPhos/PDGFB in BCPAP cells (C) and quantification of total and phospho-AKT band 
intensities (D). qPCR analyses showing the effect of transient overexpression of LETM1 on mRNA expression of PDGFB, PDGFRB and 
THBS4 in BCPAP cells (E). White and green bars indicate BCPAP transfected with pcDNA3.1 and pcDNA3.1/LETM1-Myc plasmids, 
respectively. Comparisons of the average means were performed with the Mann-Whitney U-test. Data are presented as the means ± SD. 
**P < 0.01, *** P < 0.001. All P-values are two-sided. 
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Remarkably, high LETM1 expression was also positively 
related to glycolysis/gluconeogenesis and cellular growth 
signaling pathway gene sets. Otto Warburg hypothesized 
that cancer cell proliferation is facilitated by anaerobic 
glycolysis known as fermentation. As a result, cancer 
cell should have dysfunctional mitochondria [25, 26]. 
However, metabolic heterogeneity may have an impact 
on tumor behavior and drug responsiveness [11, 13]. Our 
study implied that the mitochondrial protein LETM1 may 
enhance ATP generation in cancer cells. Based on the 
resulting increase in energy supply, cancer cells might be 
able to generate their own proliferation signal. 
The binding of insulin with its ligand specific 
receptor increases glucose metabolism, lipid synthesis 
and cellular proliferation via PKB/AKT signaling [27, 28]. 
In fact, dysregulation of PKB/AKT signaling provokes a 
broad range of diseases such as cancer, diabetes and heart 
disease [29, 30]. CTMP was first identified as a PKB/AKT 
binding partner with tumor-suppressor function. PKB/
AKT is negatively regulated by the binding of CTMP 
with the C-terminal regulatory domain of pPKB/AKT 
[31, 32]. Together with CTMP, LETM1 is associated with 
mitochondrial morphology via optic atrophy 1 (OPA1) 
regulation [33]. And, a recent report demonstrated that 
LETM1 and CTMP participate in insulin signaling via 
regulation of PKB/AKT activity [18]. Our GSEA and qRT-
PCR results also supported that these LETM1-CTMP-
PKB/AKT signaling network might be operational. Taken 
together, these data suggest that LETM1 might enhance 
AKT activation. However, this hypothesis must be tested 
in future studies.
A new finding in this study was the relation of 
LETM1 with PDGF signaling via YAP1 transactivation. 
Mammalian Hippo signaling induces inactive YAP1 
phosphorylation through MST1/2-LATS1/2 signal 
propagation [22, 34]. Whereas, activation of receptor 
tyrosine kinase (RTK) or G-protein coupled receptor 
(GPCR) turns off Hippo signaling via PI3K activation [23, 
24, 35]. Finally, YAP1 moves into nucleus and induces the 
transcriptions of YAP1 target genes with cell-type specific 
manner [36]. Based on our volcano plot presenting 
increased mRNA expressions of PDGFB and CORO2B, 
representative YAP1 target genes [21], we hypothesized 
that YAP1 transactivation by PI3K/AKT might be linked 
to PDGFB up-regulation in high LETM1 PTC, supported 
by the data from our IF and IHC-P. PDGF is a growth 
factor promoting cell growth and division especially 
in blood vessel formation [37]. Up-regulation of PDGF 
signal in cancer cells results in increased proliferation and 
cell migration by MEK/ERK activation and lamellipodia/
filopodia formation [38, 39]. Compatibly, LETM1 over-
expression increased risks of LVI and LNM in our clinical 
data analyses.
In summary, our bioinformatics and clinical 
analyses consistently indicated that LETM1 is associated 
with mitochondrial function and PKB/AKT signaling. 
Moreover, YAP1 transactivation might have a pivotal role 
in LETM1-induced PDGF signaling activation. Future 
study will be focusing on further mechanistic explanations 
of LETM1-PKB/AKT-YAP1-PDGF signal pathway to 
develop new druggable targets for invasive or metastatic 
thyroid cancers. 
Table 1: Protein expression levels of YAP1 and PDGFB according to LETM1 expression status
Patients with no/focal 
staining
Patients with moderate
to strong staining P-value
N = 94 (%) N = 83 (%)
YAP1 staining
 Focal 19 (20.2) 9 (10.8)
0.213 Moderate 58 (61.7) 55 (66.3)
 Strong 17 (18.1) 19 (22.9)
YAP1 localization
Cytosol 17 (18.1) 1 (1.2)
0.001Nucleus 51 (54.3) 60 (72.3)
Cytosol+ Nucleus 26 (27.6) 22 (26.5)
PDGFB staining
Negative 17 (18.1) 3 (3.6)
0.007
  Focal 26 (27.6) 16 (19.3)
  Moderate 22 (23.4) 24 (28.9)
  Strong 29 (30.9) 40 (48.2)
All P-values were calculated from comparisons between three or four groups in linear by linear association.
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Figure 4: Subcellular localization of YAP1 is modified by LETM1 over-expression or silencing. (A) Representative 
immunofluorescence staining indicating increased nuclear YAP1 translocation as a result of LETM1 overexpression, mediated via the 
PI3K-PKB/AKT signaling pathway in BCPAP cells. White arrow indicates nucleus. (B) Representative western blot analyses indicating 
the effect of LY294002 on AKT phosphorylation. (C) Immunofluorescence staining demonstrating the effect of siLETM1 on YAP1 nuclear 
signal. White arrows indicate nuclei. SC: scramble SiRNA. (D) Western blot analyses showing the effect of siLETM1 on total/phospho-
PKB/AKT and PDGFB in BCPAP cells. (E) qPCR analyses showing the effect of LETM1 silencing on mRNA expression of PDGFB, 
PDGFRB and THBS4 in BCPAP cells. (F) Western blot analyses showing the effect of siLETM1 on total/phospho-PKB/AKT and OxPhos/
PDGFB in 8505C cells. (G) qPCR analyses showing the effect of LETM1 silencing on mRNA expression of PDGFB, PDGFRB and THBS4 
in 8505C cells. Comparisons of the mean values were performed with the Mann-Whitney U-test. Data are presented as the means ± SD. 
** P < 0.01, *** P < 0.001. All P-values are two-sided. (H) Representative results of immunohistochemical staining using anti-LETM1 and 
YAP1 antibodies (200 x). Case #1, cytosolic localization of YAP1 in PTCs showing no LETM1 staining. Cases #2–4, nuclear accumulation 
of YAP1 in PTCs showing strong LETM1 staining. Red boxes indicate the areas magnified at the next high power field (far right panel). 
Oncotarget66735www.impactjournals.com/oncotarget
Table 2: Clinicopathologic characteristics according to LETM1 expression status
Patients with no/focal 
staining
Patients with moderate
to strong staining P-value
N = 94 (%) N = 83 (%)
Age (years) 42.4 ± 14.8 46.5 ± 14.2 0.111a
Gender (Male:Female) 18 (19.1) : 76 (80.9) 13 (15.7) : 70 (84.3) 0.543b
Tumor Size (cm) 2.30 ± 1.20 2.23 ± 0.93 0.661a
Extrathyroidal Extension
Negative 31 (33.0) 24 (28.9)
0.560b
  Positive 63 (67.0) 59 (71.1)
Multifocality
  Negative 68 (72.3) 64 (77.1)
0.467b  Positive 26 (27.7) 19 (22.9)
Bilaterality
  Negative 77 (81.9) 70 (84.3)
0.668b
  Positive 17 (18.1) 13 (15.7)
Lymphovascular invasion
  Negative 72 (76.6) 39 (47.0) < 0.001b
  Positive 22 (23.4) 44 (53.0)
Lymph node metastasis
  Negative 53 (56.4) 31 (37.3) 0.011b
  Positive 41 (43.6) 52 (62.7)
Tumor Stage
  T1 17 (18.1) 18 (21.7)
  T2 14 (14.9) 6 (7.2) 0.312b
  T3 57 (60.6) 56 (67.5)
  T4a/b 6 (6.4) 3 (3.6)
Lymph Node Stage
 N0 53 (56.4) 31 (37.3)
0.041b N1a 31 (33.0) 39 (47.0)
 N1b 10 (10.6) 13 (15.7)
Distant Metastasis
 Negative 93 (98.9) 80 (96.4) 0.255b
 Positive 1 (1.1) 3 (3.6)
TNM Stage
 I 46 (48.9) 32 (38.6)
0.658c
 II 2 (2.1) 4 (4.8)
 III 21 (22.3) 19 (22.9)
 IVA 22 (23.4) 26 (31.3)
 IVB 2 (2.1) 1 (1.2)
 IVC 1 (1.2) 1 (1.2)
aData are presented as means ± SD and P-values were calculated by an independent samples t-test. 
bP-values were calculated by pair-wise comparison using Pearson’s χ2 test or Fisher’s exact test.
cP-values were calculated by comparison between three or four groups in linear by linear association.
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MATERIALS AND METHODS
Subjects and clinical data
A total of 177 patients (31 male and 146 female) 
who underwent thyroidectomy with central neck node 
dissection for the management of conventional PTC 
between March 2014 and December 2014 at Severance 
Hospital, Yonsei Cancer Center, Seoul, South Korea were 
enrolled in the study. Samples were taken from the center 
of the cancer and validated by hematoxylin-eosin staining. 
On histological examination, > 90% of the cells were 
confirmed to be thyroid cancer cells. All protocols were 
approved by the institutional review board of Severance 
Hospital.
RNA isolation and real-time PCR
Total RNA was extracted from fresh frozen tissues 
by Trizol reagent (Invitrogen, Carlsbad, CA, USA), and 
the RNA quality was verified using a 2100 Bioanalyzer 
System (Agilent Technologies, Santa Clara, CA, USA). 
Complementary DNA (cDNA) was prepared from total 
RNA using M-MLV Reverse Transcriptase (Invitrogen) 
and oligo-dT primers (Promega, Madison, WI, USA). 
Quantative RT-PCR (qRT-PCR) was performed using a 
QuantiTect SYBR® Green RT-PCR Kit (Qiagen, Valencia, 
CA, USA). Relative expression was calculated using the 
StepOne™ Real-Time PCR System (Applied Biosystems, 
Foster City, CA, USA). Primers used in qRT-PCR are 
listed in Supplementary Table S2. qRT-PCR experiments 
were repeated three times, and each experiment was 
performed in triplicate.
Cell culture and transfection
The human thyroid cancer cell lines BCPAP and 
8505C were cultured in RPMI-1640 medium (Hyclone, 
UT, USA) containing 10% fetal bovine serum (Life 
Technologies, Carlsbad, CA) and 1% penicillin/
streptomycin (Life Technologies). The cells were 
transfected transiently with pcDNA3.1/LETM1-Myc 
using jetPEI (Polyplus transfection, Illkirch, France).
Small interfering RNA (siRNA) transfection and 
reagents
To knock down endogenous LETM1, cells were 
transiently transfected with 10 μM chemically synthesized 
siRNAs (sc-89079, Santa Cruz Biotechnology) targeting 
Table 3: Multivariate analysis of the association of lymphovascular invasion (LVI) with LETM1 
expression levels
LVI
Odds ratio 95% CI P-value
Moderate to strong staining a 3.690 1.934–7.042 < 0.001
Moderate to strong staining b 3.900 1.886–8.066 < 0.001
Moderate to strong staining c 3.455 1.537–7.766 0.003
aAdjusted for age and sex.
bIn addition to adjustmenta, adjusted for tumor size, multifocality, bilaterality, ETE, LNM, T staging, and M staging.
cIn addition to adjustmentb, adjusted for YAP1 staining, YAP1 localization and PDGFB staining.
Abbreviations: ETE, extrathyroidal extension; LNM, lymph node metastasis; LVI, lymphovascular invasion; CI, confidence 
interval.
Table 4: Multivariate analysis of the association of lymph node metastases (LNM) with LETM1 
expression levels
LNM
Odds ratio 95% CI P-value
Moderate to strong staining a 2.177 1.189–3.986 0.012
Moderate to strong staining b 2.388 1.115–5.114 0.025
Moderate to strong staining c 3.043 1.282–7.225 0.012
aAdjusted for age and sex.
bIn addition to adjustmenta, adjusted for tumor size, multifocality, bilaterality, ETE, LVI, T staging, and M staging.
cIn addition to adjustmentb, adjusted for YAP1 staining, YAP1 localization and PDGFB staining.
Abbreviations: ETE, extrathyroidal extension; LNM, lymph node metastasis; LVI, lymphovascular invasion; CI, confidence 
interval.
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LETM1 or with non-silencing control siRNA using 
Transfection Reagent, according to the manufacturer’s 
recommendations. LY294002 was purchased from Cayman 
(Ann Arbor, MI, USA). All experiments were performed in 
duplicate and were repeated at least three times.
Immunoblot analysis
Immunoblot analysis was performed using standard 
methods with commercially available antibodies: anti-
LETM1 (HPA 011029, Sigma-Aldrich, St. Louis, 
Missouri, USA), anti- Phospho-AKT (Ser473) (#9271, 
Cell Signaling, Danvers, MA, USA), anti-AKT (#9272, 
Cell Signaling), anti-YAP1 (#14074, Cell Signaling), anti-
PDGFB (HPA-011972, Sigma), Mitoprofile Total OxPhos 
Rodent WB Antibody Cocktail (Mitosciences/Abcam, 
Cambridge, MA, ab110413), anti-HSP60 (#12165, 
Cell Signaling) and anti-Actin (sc-1616, Santa Cruz 
Biotechnology, Dallas, TX, USA). The signal intensities 
on western blots were quantified using ImageJ software.
Immunofluorescence staining
The cells were plated on coverslips in six-
well plates. At 2 days after transient transfection with 
pcDNA3.1/Myc-LETM1 using jetPEI transfection reagent 
(Polyplus Transfection, Illkirch, France) (or At 2 days 
after transfection with siRNA-LETM1 using RNAiMAX 
transfection reagent (Invitrogen, CA, USA)), the cells were 
subjected to immunofluorescence staining as described 
previously [40]. The cells were fixed and permeabilized 
using conventional methods, and then blocked in 1% 
bovine serum albumin (BSA). Thereafter, the cells were 
incubated with anti-YAP1 (#14074, Cell Signaling) and 
anti-LETM1 (sc-271234, Santa Cruz Biotechnology, 
Dallas) antibodies for double immunostaining at a 1:100 
dilution in 1% BSA for 24 h at 4 °C. After washing, cells 
were incubated with FITC (Fluorescein isothiocyanate)-
conjugated pure donkey anti-rabbit and Cy3 (Cyanine)-
conjugated pure donkey anti-mouse antibodies (Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA, USA) 
at a 1:100 dilution in 1% BSA for 1 h at room temperature 
in dark. After washing the cells, cells on the coverslips were 
mounted on glass slides using mounting medium with 4, 
6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, 
Inc., Burlingame, CA, USA) and visualized with a Zeiss 
LSM710 confocal microscope (Carl Zeiss AG, Jena, 
Germany). All experiments were performed in duplicate 
and were repeated at least five times.
Measurement of oxygen consumption rate and 
glycolysis
Cells overexpressing or silenced with respect 
to LETM1 were subjected to mitochondrial oxygen 
consumption rate (OCR) and extracellular acidification 
rate (ECAR) measurements using an XF-24 analyzer 
(Seahorse Bioscience Inc, North Billerica, MA). Three 
baseline measurements of the OCR and ECAR were made.
Immunohistochemical analysis
Formalin fixed paraffin-embedded (FFPE) tissue 
sections (4 μm thick) were deparaffinized and re-hydrated 
in xylene and a graded series of ethanol, respectively. 
Antigens were retrieved in 0.01 M citrate buffer (pH 6.0) 
by microwaving for 10 min. To inactivate endogenous 
peroxidases, the tissue sections were placed in 3% 
hydrogen peroxide for 5 min and then blocked for 10 min 
with normal goat serum. The primary antibodies used for 
this study were anti-LETM1, anti-PDGFB, and anti-YAP1. 
Staining scores were assigned as follows: 1, no staining; 2, 
weak or focal staining; 3, moderate staining in most cells; 
and 4, strong staining in most cells.
Public data and statistical analysis
Public repository microarray data from The Cancer 
Genome Atlas (TCGA, https://tcga-data.nci.nih.gov/
tcga/) and the Gene Expression Omnibus (GEO) of NCBI 
(Gene expression data available at www.ncbi.nlm.nih.gov/
projects/geo; accession no. GSE33630) were subjected 
to GSEA. Data from the GeneNetwork (a free scientific 
web resource, http://www.genenetwork.org/) were also 
subjected to analysis. Statistical analysis was carried out 
using SPSS version 20.0 for Windows (IBM Corporation, 
Armonk, New York, USA) or GraphPad Prism (GraphPad 
Software, Inc., San Diego, CA, USA). Data are presented 
as the means ± SD. All P-values are two sided.
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